Europe T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)
The Europe T cell therapy market was valued at US$ 699.24 million in 2022 and is expected to reach US$ 2,345.49 million by 2030; it is estimated to grow at a CAGR of 16.3% from 2022 to 2030.
Increasing Number of T-Cell Therapy Approvals Drives the Europe T Cell Therapy Market
Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approvals. For instance,
In 2023: The European Commission has granted approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. A 4-1BB costimulatory domain found in CAR T-cell therapy augments the expansion and persistence of CAR T cells. Adults with high grade B-cell lymphoma (HGBCL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) who are refractory to first-line chemotherapy or who relapsed within a year of finishing treatment are eligible for this treatment.
In 2022: With approval from the European Committee for Medicinal Products for Human Use (CHMP), Ebvallo from Atara Biotherapeutics is set to become the world's first licensed allogeneic T-cell therapy.
In 2022: Kite, a Gilead Company, announced that Yescarta (axicabtagene ciloleucel) has been approved by the European Commission for the treatment of adult patients with high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL) who are refractory to first-line chemotherapy or who relapse within a year of finishing it.
Thus, the increasing number of approvals for T-cell therapy is fueling the market growth.
Europe T Cell Therapy Market Overview
The European T-cell therapy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Countries such as Germany and the UK are expected to be the largest contributors to the market in this region. The rising prevalence of hematologic malignancies and solid tumors and the subsequent rise in approval of T-cell therapy are the major factors driving the market growth in Europe.
According to National Health Service (NHS), ~800 people in the UK are diagnosed with acute lymphoblastic leukemia yearly, and ~ 5,500 people in England are diagnosed with B-cell lymphoma annually. Due to the prevalence of leukemia and lymphoma in the UK, people opt for T-cell therapy to treat these cancers. Owing to the awareness and positive results of T-cell therapies, NHS has struck deals with various companies, such as AstraZeneca, to expand access to personalized CAR T-cell therapies.
Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Europe T Cell Therapy Market Segmentation
The Europe T cell therapy market is segmented into modality , therapy type, indication, and country.
Based on modality, the Europe T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.
Based on therapy type, the Europe T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.
Based on indication, the Europe T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.
Based on country, the Europe T cell therapy market is segmented into Germany, UK, France, Italy, Spain, the Rest of Europe. Germany dominated the Europe T cell therapy market in 2022.
Bristol-Myers Squibb Co, Gilead Sciences Inc, Immunocore Holdings Plc, Innovent Biologics Inc, Janssen Global Services LLC, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Europe T cell therapy market.
Increasing Number of T-Cell Therapy Approvals Drives the Europe T Cell Therapy Market
Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approvals. For instance,
In 2023: The European Commission has granted approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. A 4-1BB costimulatory domain found in CAR T-cell therapy augments the expansion and persistence of CAR T cells. Adults with high grade B-cell lymphoma (HGBCL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) who are refractory to first-line chemotherapy or who relapsed within a year of finishing treatment are eligible for this treatment.
In 2022: With approval from the European Committee for Medicinal Products for Human Use (CHMP), Ebvallo from Atara Biotherapeutics is set to become the world's first licensed allogeneic T-cell therapy.
In 2022: Kite, a Gilead Company, announced that Yescarta (axicabtagene ciloleucel) has been approved by the European Commission for the treatment of adult patients with high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL) who are refractory to first-line chemotherapy or who relapse within a year of finishing it.
Thus, the increasing number of approvals for T-cell therapy is fueling the market growth.
Europe T Cell Therapy Market Overview
The European T-cell therapy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Countries such as Germany and the UK are expected to be the largest contributors to the market in this region. The rising prevalence of hematologic malignancies and solid tumors and the subsequent rise in approval of T-cell therapy are the major factors driving the market growth in Europe.
According to National Health Service (NHS), ~800 people in the UK are diagnosed with acute lymphoblastic leukemia yearly, and ~ 5,500 people in England are diagnosed with B-cell lymphoma annually. Due to the prevalence of leukemia and lymphoma in the UK, people opt for T-cell therapy to treat these cancers. Owing to the awareness and positive results of T-cell therapies, NHS has struck deals with various companies, such as AstraZeneca, to expand access to personalized CAR T-cell therapies.
Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Europe T Cell Therapy Market Segmentation
The Europe T cell therapy market is segmented into modality , therapy type, indication, and country.
Based on modality, the Europe T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.
Based on therapy type, the Europe T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.
Based on indication, the Europe T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.
Based on country, the Europe T cell therapy market is segmented into Germany, UK, France, Italy, Spain, the Rest of Europe. Germany dominated the Europe T cell therapy market in 2022.
Bristol-Myers Squibb Co, Gilead Sciences Inc, Immunocore Holdings Plc, Innovent Biologics Inc, Janssen Global Services LLC, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Europe T cell therapy market.
1. INTRODUCTION
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Europe T Cell Therapy Market, by Country (US$ Million)
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. EUROPE T CELL THERAPY MARKET - KEY INDUSTRY DYNAMICS
4.1 Market Drivers:
4.1.1 Growing Burden of Cancer Worldwide
4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:
5. T CELL THERAPY MARKET - EUROPE MARKET ANALYSIS
5.1 Europe T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
6. EUROPE T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY MODALITY.
6.1 Overview
6.2 Europe T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
6.3.1 Overview
6.3.2 Research: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
6.4.1 Overview
6.4.2 Commercialized: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7. EUROPE T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY THERAPY TYPE
7.1 Overview
7.2 Europe T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
7.3.1 Overview
7.3.2 CAR T-cell Therapy: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
7.4.1 Overview
7.4.2 T-cell Receptor (TCR)-based: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8. EUROPE T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY INDICATION
8.1 Overview
8.2 Europe T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
8.3.1 Overview
8.3.2 Hematologic Malignancies: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.3.3 Europe T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
8.4.1 Overview
8.4.2 Solid Tumor: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9. EUROPE T CELL THERAPY MARKET - COUNTRY ANALYSIS
9.1 Europe
9.1.1.1 Europe T Cell Therapy Market, by Country
9.1.1.2 UK
9.1.1.2.1 UK Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.2.2 UK: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.2.3 UK: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.2.4 UK: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.2.4.1 UK: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.3 Germany
9.1.1.3.1 Germany: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.3.2 Germany: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.3.3 Germany: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.3.4 Germany: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.3.4.1 Germany: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.4 France
9.1.1.4.1 France: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.4.2 France: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.4.3 France: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.4.4 France: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.4.4.1 France: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.5 Italy
9.1.1.5.1 Italy: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.5.2 Italy: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.5.3 Italy: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.5.4 Italy: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.5.4.1 Italy: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.6 Spain
9.1.1.6.1 Spain: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.6.2 Spain: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.6.3 Spain: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.6.4 Spain: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.6.4.1 Spain: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.7 Rest of Europe
9.1.1.7.1 Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.7.2 Rest of Europe: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.7.3 Rest of Europe: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.7.4 Rest of Europe: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.7.4.1 Rest of Europe: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10. T CELL THERAPY MARKET-INDUSTRY LANDSCAPE
10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. COMPANY PROFILES
11.1 Immunocore Holdings Plc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Legend Biotech Corp
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Janssen Global Services LLC
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Gilead Sciences Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Bristol-Myers Squibb Co
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Novartis AG
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Innovent Biologics Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
12. APPENDIX
12.1 About Us
12.2 Glossary of Terms
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Europe T Cell Therapy Market, by Country (US$ Million)
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. EUROPE T CELL THERAPY MARKET - KEY INDUSTRY DYNAMICS
4.1 Market Drivers:
4.1.1 Growing Burden of Cancer Worldwide
4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:
5. T CELL THERAPY MARKET - EUROPE MARKET ANALYSIS
5.1 Europe T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
6. EUROPE T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY MODALITY.
6.1 Overview
6.2 Europe T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
6.3.1 Overview
6.3.2 Research: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
6.4.1 Overview
6.4.2 Commercialized: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7. EUROPE T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY THERAPY TYPE
7.1 Overview
7.2 Europe T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
7.3.1 Overview
7.3.2 CAR T-cell Therapy: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
7.4.1 Overview
7.4.2 T-cell Receptor (TCR)-based: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8. EUROPE T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY INDICATION
8.1 Overview
8.2 Europe T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
8.3.1 Overview
8.3.2 Hematologic Malignancies: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.3.3 Europe T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
8.4.1 Overview
8.4.2 Solid Tumor: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9. EUROPE T CELL THERAPY MARKET - COUNTRY ANALYSIS
9.1 Europe
9.1.1.1 Europe T Cell Therapy Market, by Country
9.1.1.2 UK
9.1.1.2.1 UK Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.2.2 UK: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.2.3 UK: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.2.4 UK: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.2.4.1 UK: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.3 Germany
9.1.1.3.1 Germany: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.3.2 Germany: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.3.3 Germany: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.3.4 Germany: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.3.4.1 Germany: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.4 France
9.1.1.4.1 France: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.4.2 France: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.4.3 France: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.4.4 France: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.4.4.1 France: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.5 Italy
9.1.1.5.1 Italy: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.5.2 Italy: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.5.3 Italy: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.5.4 Italy: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.5.4.1 Italy: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.6 Spain
9.1.1.6.1 Spain: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.6.2 Spain: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.6.3 Spain: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.6.4 Spain: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.6.4.1 Spain: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.7 Rest of Europe
9.1.1.7.1 Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.7.2 Rest of Europe: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.7.3 Rest of Europe: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.7.4 Rest of Europe: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.7.4.1 Rest of Europe: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10. T CELL THERAPY MARKET-INDUSTRY LANDSCAPE
10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. COMPANY PROFILES
11.1 Immunocore Holdings Plc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Legend Biotech Corp
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Janssen Global Services LLC
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Gilead Sciences Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Bristol-Myers Squibb Co
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Novartis AG
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Innovent Biologics Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
12. APPENDIX
12.1 About Us
12.2 Glossary of Terms
